- Global Pharma News & Resources

PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference

INCLINE VILLAGE, Nev., Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ : PDLI ) announces that John McLaughlin, PDL's chief executive officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference next week in New York City.  The session will be webcast live and will occur on Thursday, September 6, 2018, at 2:35 p.m. EDT.

To access the live and subsequently archived webcast of the presentation, go to the Company's website at and go to the Investor Relations section and select "Events & Presentations."  Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.  The archived webcast will be available for at least seven days following the presentation. 

About PDL BioPharma, Inc.

We seek to provide a significant return for our stockholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. In 2012, we began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, we have consummated seventeen of such transactions, of which nine are active and outstanding. We have one debt transaction outstanding, representing deployed of $20.0 million: CareView; we have one hybrid royalty/debt transaction outstanding, representing deployed capital of $44.0 million: Wellstat Diagnostics; and we have five royalty transactions outstanding, representing deployed capital of $416.1 million, respectively: KYBELLA®, AcelRx, University of Michigan, Viscogliosi Brothers and Depomed. Our equity and loan investments in Noden represent deployed capital of $179.0 million, respectively, and our converted equity and loan investment in LENSAR represents deployed capital of $40.0 million.

NOTE:  PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all rights therein.

Editor Details

Related Links

Last Updated: 31-Aug-2018